BioWorld-International-2009-10-21
Cytos Shares Plunge as Vaccine Trial Misses Main Endpoint
Cytos Shares Plunge as Vaccine Trial Misses Main Endpoint
Cytos Biotechnology AG lost almost one-third of its value Friday on news that its therapeutic vaccine for nicotine addiction failed to show efficacy in a Phase II study. (BioWorld International)

